12:00 AM
 | 
Dec 07, 2009
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Astellas deal

Seattle Genetics and Astellas' Agensys Inc. subsidiary added additional targets to a 2007 deal to develop and commercialize antibody-drug conjugates (ADCs) for cancer....

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >